spacer
home > ebr > summer 2017 > cut and paste
PUBLICATIONS
European Biopharmaceutical Review

Cut and Paste

The successful sequencing of the human genome in 2003 was a momentous accomplishment and has turned out to be a gift that keeps on giving. A renewed understanding of biology and pathophysiology has advanced the knowledge and utility of many existing fields, such as rare diseases, genetic disorders and cancer, to name but three. As a result, there has been an explosion of new techniques to diagnose, prevent and treat pathologies. This singular event has also led to the spawning of new areas like next-generation sequencing and gene-editing. The latter is a disruptive emerging technology that has the potential to alter the way we view genetic or gene-related diseases, changing many from being lethal to chronic at worst and curable at best.

CRISPR-Cas9


Heraclitus, a Greek philosopher, is credited with saying that ‘change is the only constant in life’; in science, this continues to prove true. In the 90s, gene therapy was hailed as the next big thing at the cutting edge of science. Revolutionary as it was, it has stuttered and spluttered, failing to break into the realms of mainstream therapies. Gene therapy involves using a neutered virus (known as a viral vector) to deliver a synthetic functioning copy of a gene into cells. The trouble is that there is no control over where the gene will end up in the three billion DNA base pairs, hence it is a rather blunt instrument.

While gene therapies were still experiencing teething problems, two bacteriologists serendipitously discovered a process that would progress genetic science. They observed that bacteria, when defending themselves from a virus, would replicate the virus’s DNA and attach a key enzyme called Cas9. This would then unlock the DNA of the virus, break and disable it, thereby rendering the virus impotent. Mimicking this clever process from nature, clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 technology was born.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Jimmy Muchechetere is a Healthcare and Biotech Research Analyst at Investec, having joined the financial industry in 2011 at Williams De Broë (now Investec Wealth & Investment) as a Research Intern. He is responsible for the equity research of all pharma as well as other healthcare and biotech companies across the globe. Jimmy also oversees the smooth running of the research department’s international service and is a registered medical doctor with seven years’ experience.
spacer
Jimmy Muchechetere
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Signant Health Launches Partner Program to Team with Clinical Research Organizations (CROs) Committed to Improving Clinical Trials with Patient-Centric Technology

PHILADELPHIA – August 12, 2019: Signant Health (signanthealth.com), a leading provider of technology for clinical research, today launches the Signant Health Partner Program, a significant investment the company is making to enable clinical research organizations (CROs) to better serve sponsors in the areas of Patient Data, Patient Experience, Clinical Supplies, and Endpoint Quality Solutions. By becoming a Signant Partner, CROs will benefit from new commercial and operational advantages that only come with membership.
More info >>

White Papers

Backward Thinking: The Reverse Engineering of A Pressurized Metered Dose Inhaler

Development of a generic equivalent to a current marketed pressurized metered dose inhaler (pMDI) product brings immense challenges. Thorough analysis is critical to gain a comprehensive understanding of the physical attributes and pharmaceutical performance of the reference marketed product. Many factors need to be assessed, understood and combined in order to successfully develop a generic pMDI which will meet the regulatory and quality requirements as an equivalent product in the anticipated target market. Significant information about the reference marketed product can be obtained from a thorough review of published literature, specifically the Summary of Product Characteristics (SPC) and Patient Information Leaflet (PIL). Additionally, baselining the reference marketed product for pharmaceutical performance offers a working target specification for in-vitro correlation. It will ensure the smoothest possible path to commercialization and maximize return on investment. In addition, baselining of the reference marketed product is done to understand batch-to-batch variability and product performance over the stated shelf life to establish targets for critical quality attributes (CQAs), which can be applied to the generic equivalent pMDI.
More info >>

 
Industry Events

CPhI Worldwide

5-7 November 2019, Frankfurt, Germany

Join the World's Largest Pharma Event As it Celebrates its 30th Anniversary! Taking place from 5-7 November 2019 in Frankfurt, Germany, the event will bring together more than 45,000 visiting pharma professionals from around the globe and over 2,500 exhibiting pharma companies from every stage of the pharmaceutical supply chain - from ingredients and machinery to outsourcing services, packaging and more!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement